Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Sun Sets On Gleevec, Novartis Looks To New Horizons In Oncology

Executive Summary

The blockbuster leukemia drug will likely face generic competition in 2015, putting pressure on Novartis to bring new cancer drugs to market to make up for the lost sales. The company has several promising mid- to late-stage candidates in the pipeline, but developing another blockbuster the likes of Gleevec won’t be easy.

You may also be interested in...



Novartis’ Panobinostat Review Panel Could Scrutinize Survival Data

FDA’s Oncologic Drugs Advisory Committee is slated to meet on Nov. 6 to consider Novartis’ HDAC inhibitor panobinostat for relapsed multiple myeloma and may also look closely at dosing issues.

Novartis Previews Panobinostat PFS Advantage In Myeloma

Positive Phase III findings support Novartis’ plan for filing the pan-DAC inhibitor in 2014. The firm’s initial BLA for the compound, seeking accelerated approval in Hodgkin’s lymphoma, was rejected by FDA in 2011.

Novartis’ Afinitor Ambitions Set Back By Phase III Liver Cancer Failure

Announcing the failure of the Phase III EVOLVE-1 study of Afinitor in liver cancer, Novartis says that current approvals won’t be affected and that it plans to press on with Phase III studies in other indications.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel